Abstracts Archive - Page 1147 of 2425 - ACR Meeting Abstracts

Abstract Number: 2137 • 2018 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Cecilia Nalli¹, Greta Pascariello¹, Arianna Zentilin¹, Elena Raffetti², Laura Andreoli¹, Rajesh Kumar¹, Giuliana Martini³, Roberta Ottaviani¹, Cinzia Gasparotti⁴, Michele Magoni⁴, Carmelo Scarcella⁴, Francesco Donato⁵ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Epidemiology and Public Health Intervention Research group (EPHIR), Department of Public Health Sciences, Karolinska Institutet, Solna, Sweden, ³Hemostasis and Thrombosis Center, Spedali Civili of Brescia, Brescia, Italy, ⁴ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, ⁵Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Unit of Hygiene, Epidemiology, and Public Health, University of Brescia, Italy., Brescia, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterized by thrombotic and/or obstetrical manifestations mediated by antiphospholipid antibodies (aPL). By now, no population-based study…
Abstract Number: 2138 • 2018 ACR/ARHP Annual Meeting
Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Brian Ung¹, Dionne Hines², Sandhya Mehta¹, Corey Pelletier¹, Xin Wang² and Rolin Wade², ¹Celgene Corporation, Summit, NJ, ²IQVIA, Durham, NC
Background/Purpose: Methotrexate (MTX) is commonly used to treat psoriatic arthritis (PsA), yet data supporting its effectiveness in PsA are limited. This analysis describes real-world dosing,…
Abstract Number: 2139 • 2018 ACR/ARHP Annual Meeting
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Mateo Mejia Saldarriaga¹, Ivan Emil Ramirez de Oleo¹ and Beverly Johnson^2,3, ¹Internal Medicine, Jacobi Medical Center, Bronx, NY, ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucose-6-phosphate dehydrogenase deficiency (G6PD) is linked to hemolytic anemia with certain medications and is the most common enzyme deficiency worldwide. Clinical hemolysis and severity…
Abstract Number: 2140 • 2018 ACR/ARHP Annual Meeting
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Rheumatoid Arthritis: A Retrospective Study
Alisha Gupta¹, Aditya Joshi¹, Omar Saleem¹, Mary Chester-Wasko² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a derivative of quinidine, a class 1a anti-arrhythmic agent used to prevent ventricular arrhythmias and recurrent atrial fibrillation (AFib). AFib occurs…
Abstract Number: 2141 • 2018 ACR/ARHP Annual Meeting
Development of a Pediatric Glucocorticoid Toxicity Index
Paul Brogan¹, Raymond P. Naden², Stacy P. Ardoin³, Jennifer C. Cooper⁴, Fabrizio De Benedetti⁵, Jean-Francois Dicaire⁶, Despina Eleftheriou⁷, Brian M. Feldman⁸, Jon Goldin⁹, Seth E. Karol¹⁰, Eli Miloslavsky¹¹, Fiona Price-Kuehne¹², David Skuse⁹, Constantine A. Stratakis¹³, Nicholas Webb¹⁴ and John H. Stone¹⁵, ¹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁶Pinnacle Inc., Quebec, QC, Canada, ⁷Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Psychiatry, Great Ormond Street Hospital / University College London, London, United Kingdom, ¹⁰Oncology, St. Jude's Children's Hospital, Memphis, TN, ¹¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology, Cambridge University Hospitals, Cambridge, United Kingdom, ¹³National Institute of Child Health and Human Development, Bethesta, MD, ¹⁴Pediatrics, Manchester University, Manchester, United Kingdom, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A Glucocorticoid Toxicity Index app (GTI 2.0) is now used as a clinical trial outcome measure in adults, but glucocorticoid (GC) toxicity issues in…
Abstract Number: 2142 • 2018 ACR/ARHP Annual Meeting
Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study
Mary A. De Vera^1,2,3, Nicole W. Tsao^1,2,3, Eric C. Sayre² and Alyssa Howren^1,2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada
Background/Purpose: Infection risk is one of the concerns regarding therapy with conventional disease modifying antirheumatic drugs (csDMARDs) and to our knowledge no research has examined…
Abstract Number: 2143 • 2018 ACR/ARHP Annual Meeting
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Linh Truong¹ and Maida Wong², ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Division of Rheumatology, University of California, Irvine, Orange, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…
Abstract Number: 2144 • 2018 ACR/ARHP Annual Meeting
Epidemiological Characterisitics of Psoriatric Arthritis: A Nationwide Study of Inpatient Hospitalisations in 2014
Vagishwari Murugesan and Jennifer Tran, Internal Medicine, Medstar Washington Hospital Center, Washington, DC
Background/Purpose:: Psoriatic arthritis is a seronegative inflammatory arthritis associated with Psoriasis. Using the National Inpatient Sample (NIS) we studied the epidemiological characteristics of inpatients admissions…
Abstract Number: 2145 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Heart Failure with Prolonged Use of Hydroxychloroquine in Patients with Rheumatoid Arthritis
Elena Myasoedova¹, Reto Kurmann², Cynthia S. Crowson³, John M. Davis III¹ and Rekha Mankad², ¹Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Hydroxychloroquine (HCQ) is commonly prescribed for patients with rheumatoid arthritis (RA). Cardiotoxicity is a rare but potentially life-threatening side effect of HCQ and may…
Abstract Number: 2146 • 2018 ACR/ARHP Annual Meeting
A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy
Amanda Worme¹, Leonardo Tamariz², Ana Palacio², Zsuzsanna Nemeth³ and Mathew Farbman⁴, ¹Internal Medicine, University of Miami Miller School of Medicine at Holy Cross Hospital, Fort Lauderdale, FL, ²Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, ³Health Informatics, University of Miami Miller School of Medicine, Miami, FL, ⁴Rheumatology, University of Miami Miller School of Medicine at Holy Cross Hospital, Fort Lauderdale, FL
Background/Purpose: HCQ is one of the most common DMARD(s) used in treatment of several rheumatologic diseases, including RA and SLE. Although rare, retinal toxicity remains…
Abstract Number: 2147 • 2018 ACR/ARHP Annual Meeting
Associations between Current Cigarette Smoking and SLE-Related Cytokine and Chemokine Biomarkers Among U.S. Female Nurses without SLE
Cianna Leatherwood¹, Xinyi Liu¹, Susan Malspeis², Andrea Roberts³, Jeffrey A. Sparks¹, Elizabeth Karlson¹, Candace H. Feldman¹, Judith A. James⁴, Laura Kubzansky⁵ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴OMRF & OUHSC, Oklahoma City, OK, ⁵Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Current cigarette smoking and recent cessation (within 4 years), compared to no smoking or remote cessation, have been associated with increased anti-dsDNA+ SLE…
Abstract Number: 2148 • 2018 ACR/ARHP Annual Meeting
Prevalence and Incidence of FMF in Germany – Results of the First Retrospective Analysis of Representative Claims Data
Ivan Foeldvari¹, Katharina Boehm², Thomas Kramps² and Lukas Mayerhoff³, ¹Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ²Novartis Pharma GmbH, Nuremberg, Germany, ³Elsevier GmbH, Munich, Germany
Background/Purpose: Familial Mediterranean fever (FMF) is a rare hereditary autoinflammatory disease that predominantly affects, but is not limited to, persons of Middle Eastern ancestry. In…
Abstract Number: 2149 • 2018 ACR/ARHP Annual Meeting
Assessing the Prevalence of Localized Scleroderma in Childhood Using Dministrative Claims Data from the United States
Timothy Beukelman¹, Fenglong Xie² and Ivan Foeldvari³, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile Localised Scleroderma (jlSc) is believed a rare autoimmune disease, which occurs 10 times more often then systemic sclerosis in childhood and is believed…
Abstract Number: 2150 • 2018 ACR/ARHP Annual Meeting
Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², S. Sam Lim³, Cristina Drenkard⁴ and Laura Plantinga⁵, ¹Department of Epidemiology, Emory University, Atlanta, GA, ²Durham Veterans Affairs Medical Center, Durham, NC, ³Emory University School of Medicine, Atlanta, GA, ⁴Medicine/Rheumatology, Emory University, Atlanta, GA, ⁵Department of Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lower socioeconomic status (SES) has been shown to be associated with poor physical functioning in systemic lupus erythematosus (SLE) patients; however, previous studies have…
Abstract Number: 2151 • 2018 ACR/ARHP Annual Meeting
The Impact of Obesity on SLE Disease Activity
Phildrich Teh¹, Bishoy Zakhary², Arezoo Haghshenas³ and Vaneet K. Sandhu³, ¹Internal Medicine, University of California, Riverside, Riverside, CA, ²Office of Research, Riverside University Health System, Moreno Valley, CA, ³Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Obesity is associated with increased disease severity in multiple autoimmune conditions, likely via formation of pro-inflammatory adipokines [1]. However, the role of obesity in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].